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  Recombinant baculoviruses containing the fusion (F) and 
hemagglutinin-neuraminidase  (HN)  glycoprotein  gene  of 
the  viscerotropic  velogenic  (vv)  Newcastle  disease  virus 
(NDV) isolate, Kr-005/00, and a lentogenic La Sota strain 
of the NDV were constructed in an attempt to develop an 
effective subunit vaccine to the recent epizootic vvNDV. 
The level of protection was determined by evaluating the 
c l i n i c a l  s i g n s ,  m o r t a l i t y ,  a n d  v i r u s  s h e d d i n g  f r o m  t h e  
oropharynx and cloaca of chickens after a challenge with 
vvNDV Kr-005/00. The recombinant ND F (rND F) and 
recombinant  HN  (rND  HN)  glycoproteins  derived  from 
the velogenic strain provided good protection against the 
clinical signs and mortality, showing a 0.00 PI value and 
100%  protection  after  a  booster  immunization.  On  the 
other  hand,  the  combined  rND  F + HN  glycoprotein 
derived  from  the  velogenic  strain  induced  complete 
protection  (0.00  PI  value  and  100%  protection)  and 
significantly reduced the amount of virus shedding even 
after  a  single  immunization.  The  rND  F  and  rND  HN 
glycoproteins  derived  from  the  velogenic  strain  had  a 
slightly,  but  not  significantly,  greater  protective  effect 
than the lentogenic strain. These results suggest that the 
combined rND F + HN glycoprotein derived from vvNDV 
can  be  an  ideal  subunit  marker  vaccine  candidate  in 
chickens in a future ND eradication program.
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Introduction 
  Newcastle disease (ND) is a highly contagious disease in 
poultry that is characterized by respiratory, nervous, 
enteric, and reproductive infections. ND can be divided 
into five pathotypes in chickens according to the severity 
of the disease: viscerotropic velogenic, neurotropic 
velogenic, mesogenic, lentogenic or respiratory, and 
asymptomatic enteric [2]. ND causes serious economic 
losses in poultry farms and is one of the most important 
diseases in the poultry industry.
  The ND virus (NDV) is a member of the genus Avulavirus 
and the family Paramyxoviridae [13,14]. The viral 
genome encodes six proteins from the 5' terminus to the 3' 
terminus: RNA-directed RNA polymerase (L gene), 
hemagglutinin-neuraminidase (HN gene), fusion (F gene), 
matrix (M gene), phosphoprotein (P gene), and nucleocapsid 
(NP) protein [2]. The HN and F glycoprotein on the surface 
of NDV are important for virus infectivity and 
pathogenicity, and either of these proteins can induce 
protective immunity [8,15,20,21,24,30].
  A number of live and inactivated ND vaccines are used to 
control ND. However, for commercially available ND 
vaccines, serological differentiation between birds naturally 
infected and vaccinated is impossible using a qualitative 
assay. To overcome this disadvantage, attempts have been 
made to develop a recombinant virus expressing either the 
F or HN glycoprotein of NDV in fowl poxvirus 
[3,4,7,9,10,24,27,28], vaccinia virus [16], and herpesvirus 
[6,17-19]. The recombinant ND F (rND F) or recombinant 
HN (rND HN) glycoproteins provided protective immunity 
against a NDV challenge. Makkay et al. [12] also 
suggested the possibility of serological differentiation 
between birds naturally infected with a virulent strain of 
NDV and those vaccinated with the recombinant subunit 302    Youn-Jeong Lee et al.
Table 1. Primer sequences
Primer Gene amplified size (bp) Primer sequence
F (+) for LaSota 5' TCCAGGTGCAAGATGGGCTCC 3'
1,701
F (− ) for LaSota 5' AGGGAAACCTTCGTTCCTCAT 3'
HN (+) for LaSota 5' TCAATCATGGACCGCGCCGTT 3'
1,795
HN (− ) for LaSota 5' CGCAGAAGATAGGTGATACAA 3'
F (+) for Kr-005/00 5' ACATTCAGGACACAATATGGG 3'
1,719
F (− ) for Kr-005/00 5' CACAGGCTGCTGTTGGGTAT 3'
HN (+) for Kr-005/00 5' ACAAGAGTCAATCATGGACCG 3'
1,779
HN (− ) for Kr-005/00 5' TCGTCTTCCCAACCATCCTAT 3'
vaccine using rND F or rND HN glycoproteins.
  Kamiya et al. [8] also reported the protective effects and 
antibody response of rND F and rND HN derived from the 
virulent and avirulent NDV strains. They used the D26 and 
Miyadera strains as avirulent and virulent strains, 
respectively, to evaluate the protective effects and the rND 
F glycoprotein derived from the avirulent strain had a 
lower protective effect.
  Here, we expressed the rND F and rND HN glycoproteins 
derived from the lentogenic La Sota strain and the Korean 
vvNDV Kr-005/00 strain, respectively, using a recombinant 
baculovirus. The synergistic effects of the combined rND F 
and rND HN glycoproteins were also compared. The 
efficacy of the recombinant baculovirus vaccine was 
evaluated in more detail by comparing the clinical signs, 
mortality, and amount of virus shedding from the 
oropharynx and cloaca of vaccinated chickens after a 
challenge. The aim of this study was to develop a more 
effective vaccine to prevent ND and to minimize the 
amount of virus shedding and spreading after a challenge 
with vvNDV in vaccinated birds. The combined rND F and 
rND HN glycoproteins derived from vvNDV were 
evaluated as subunit marker vaccines that might be used as 
an effective monitoring tool by differentiating the 
antibodies produced by natural NDV infections from those 
produced by vaccination.
Materials and Methods
Viruses and cells
  The Korean viscerotropic velogenic (vv) NDV Kr-005/00 
strain and the lentogenic La Sota strain of NDV were 
grown in 10-day-old specific pathogen free (SPF) 
embryonated chicken eggs. The Autographa californica 
nucleopolyhedrovirus (AcNPV) and recombinant baculo-
viruses were grown and assayed in either Spodoptera 
frugiperda 21 (Sf21) cells or Trichoplusia ni High Five 
(Hi5) cells in Grace’s medium (GibcoBRL, USA) 
supplemented with 10% fetal bovine serum. The virus 
re-isolation of the challenge virus was performed in 
primary chicken embryo fibroblast (CEF) cell cultures.
Construction  of  the  transfer  vectors  pBacF  and 
pBacHN
    Viral RNA was extracted directly from the infective 
allantoic fluid using an RNeasy kit (Qiagen, USA) 
according to the manufacturer’s recommendations. Four 
paired primers were used to amplify the complete coding 
sequence of the fusion (F) and Hemagglutination- 
Neuraminidase (HN) genes of the La Sota and Kr-005/00 
strains (primer sequences, Table 1).
    The purified reverse transcription-polymerase chain 
reaction products of each gene were cloned into a cloning 
vector, pCR 2.1 (Invitrogen, USA). To construct the 
transfer vectors pBacF(V) and pBacHN(V), the F and HN 
genes of the Kr-005/00 strain were excised by digestion 
with EcoR I and inserted into the EcoR I site of pBacPAK9 
(Clontech, USA). The F gene of the La Sota strain was 
excised by digestion with Xho I and BamH I, and the HN 
gene of the La Sota strain was excised by digestion with 
Not I and BamH I. The excised fragments were repaired 
with T4 polymerase and inserted into the Sma I site of 
pBacPAK9. The resulting transfer vectors were pBacF(L) 
and pBacHN(L). All transfer vectors contained the 
upstream polyhedron promoter of the inserted gene and the 
downstream polyadenylation sequences. The orientation 
of the inserted gene was examined by a restriction enzyme 
treatment and by sequencing the 5' junction region.
Transfection and selection of recombinant virus
  Sf21 cells were transfected with 0.5 μg of the transfer 
vector plasmid DNA (four each) and BacPAK6 viral DNA 
(Bsu36 I digest) using the BacPAK baculovirus expression 
system (Clontech, USA) according to the manufacturer’s 
instructions. After 72 h incubation at 27
oC, the culture 
supernatants were subjected to a plaque assay to isolate the 
recombinant viruses. The selected plaque was examined to 
confirm that the target gene had been inserted into the viral 
genome using polymerase chain reaction with the Bac1 
and Bac2 primers (Clontech, USA). Four recombinant Protection of recombinant NDV subunit vaccine    303
viruses, rND F induced from vvNDV rNDF(V), rND F 
from La Sota strain rNDF(L), rND HN from vvNDV 
rNDHN(V), and rND HN from La Sota rNDHN(L), were 
prepared using pBacF(V), pBacF(L), pBacHN(V), and 
pBacHN(L), respectively. Recombinant viruses were 
stored at 4
oC until needed.
Immunofluorescence assay
  An immunofluorescence assay was performed without 
prior fixation, as described previously [22]. Briefly, the 
Sf21 cells were infected with the recombinant at an MOI of 
5 and incubated at 27
oC for 48 h. The unfixed infected cells 
were washed with phosphate-buffered saline (PBS) and 
incubated with polyclonal chicken anti-NDV sera or 
monoclonal antibodies specific to the NDV HN 
glycoprotein for 1 h at room temperature. After washing 
with PBS, the cells were incubated with fluorescein 
isothiocyanate-conjugated anti-chicken or anti-mouse 
immuno-globulin (Cappel, USA) for 1 h at room 
temperature. The cells were washed again with PBS and 
examined for fluorescence.
Chickens
    All chickens were derived from SPF eggs of White 
Leghorn parents (Lohmann, Germany). The animals were 
housed and reared in positive-pressure isolators until they 
were immunized.
Immunization of chickens and challenge
  Sf21  cells  infected  with recombinant viruses were 
sonicated with Soniprep 150 (Sanyo, UK) at 18 Khz for 5 
min, clarified by centrifugation, mixed thoroughly using 
an Omnimixer with Montanide Incomplete Seppic 
Adjuvant (ISA-70; Seppic, France) at a ratio of 3 : 7, and 
used as antigens for immunization. For vaccination, 
chickens were inoculated intramuscularly with the 
Seppic-adjuvanted antigen (detailed doses are described in 
each Table). Each group of vaccinated and unvaccinated 
chickens was challenged with the vvNDV Kr-005/00 strain 
through an intraocular inoculation with an 10
5.5 EID50 per 
bird. vvNDV Kr-005/00 was the representative strain of 
genotype VII, which is the dominant epizootic genotype in 
Korea [11]. The chickens were kept under observation for 
14 days after infection.
Protection assay
  To examine the protective effect of each recombinant 
glycoprotein, the SPF chickens were immunized with 
infected cells containing rNDF(V), rNDF(L), rNDHN(V), 
or rNDHN(L) and the Seppic-adjuvant. In Experiment 1, 
fifty-five 5-week-old chickens were divided into 11 groups, 
in which rNDF(V) and rNDHN(V) were subdivided into 4 
groups based on the inoculum dose. Five chickens from 
each group were housed in separate isolators. All chickens 
were immunized twice at 3-week intervals and challenged 
3 weeks after the second immunization.
  In Experiment 2, 120 3-week-old chickens were divided 
into 8 groups. Four groups were immunized with 1 × 10
6 
cells of the infected lysate with an adjuvant of rNDF(V), 
rNDF(L), rNDHN(V), or rNDHN(L). Two groups were 
immunized with a half dose (0.5 × 10
6 cells) of rNDF(V) 
and rNDHN(V), and the last group was immunized with 
the combined rNDF(V) and rNDHN(V)-infected cells. 
The remaining group was used as the non-immunized 
control. Fifteen chickens in each group were housed in 
separated isolators. Three weeks after the first immunization, 
seven chickens from each group were challenged to 
evaluate the level of immunity, and the remaining eight 
chickens were given a booster immunization with the same 
antigen. Three weeks after the second immunization, the 
chickens were challenged. The protective effect was 
evaluated by observing the chickens for any clinical signs 
and mortality. The re-isolation of the challenge virus was 
carried out in CEF cells with the oropharyngeal and cloacal 
swab samples 5 day after the challenge infection. All 
chickens were sampled at 5 d post infection (dpi) including 
three dead chickens at 4 dpi, one chicken from the rND 
F(V) group and two chickens from the control group, after 
the 1st immunization in Experiment 2 (Table 3). For virus 
isolation, the swab samples were suspended in 1 ml of cell 
culture medium with antibiotics. And then the clarified 
supernatants were titrated for virus infectivity in CEF cells.
Serological assays
  The Hemagglutination inhibition (HI) test was performed 
as described in the OIE manual of standard diagnostic tests 
[23]. The level of agglutination was assessed by titling the 
plates. Only those wells in which the RBCs streamed at the 
same rate as the control wells were considered to exhibit 
hemagglutination inhibition. ELISA was performed using 
the Newcastle disease antibody detection kit (IDEXX 
Laboratories, USA) according to manufacturer’s instructions.
Statistical analyses
  For statistical analyses, the two-tailed Fisher’s exact test 
and the Student’s t-test were used for the protective 
immunity and antibody response, respectively. A p-value 
＜0.05 was considered significant.
Results
  The nucleotide sequence of the 5' junction region of the 
transfer vector indicated that the plasmid contained the 
inserted gene in the proper orientation for expression. The 
target gene inserted in the viral genome as assessed by 
polymerase chain reaction of the selected recombinant 
virus plaques (data not shown). The expression of the NDV 
glycoprotein was confirmed by indirect immunofluorescence 304    Youn-Jeong Lee et al.
Table 2. Protective effect and antibody response after immunization with the recombinant baculovirus glycoproteins derived from the
lentogenic and velogenic Newcastle disease viruses (Experiment 1)
Antigen immunized Dose (cells/bird)
Protection after 2nd
HI titer (log2 ± SD) ELISA titer
 immunization
1st* 2nd
† 1st 2nd Mortality
‡
rND F (L) 10
7 0.0 0.0    2,242** 5,421
†† 0/5
∥
rND F (V) 10
7 0.0 0.0   2,644
†† 5,861
†† 0/5
∥
10
6 0.0 0.0   1,735
†† 4,297
†† 0/5
∥
10
5 0.0 0.0     1,366** 3,100
†† 1/5
§
10
4 0.0 0.0 1,085   2,440** 0/5
∥
rND HN (L) 10
7 1.0 ± 0.7
¶ 3.4 ± 0.9
†† n.d. n.d. 1/5
§ 
rND HN (V) 10
7    2.4 ± 1.1** 3.4 ± 0.5
†† n.d. n.d. 1/5
§ 
10
6  3.8 ± 0.8
†† 3.8 ± 1.0
†† n.d. n.d. 1/5
§ 
10
5  3.8 ± 0.8
†† 3.4 ± 0.9
†† n.d. n.d. 1/5
§ 
10
4 0.0  2.4 ± 1.1** n.d. n.d. 1/5
§ 
Control − 0.0 0.0 0 0 5/5 
*3 weeks after the first immunization. 
†3 weeks after the second immunization. 
‡Number died over the number tested. 
§p ＜ 0.05 by Fisher’s
exact test. 
∥p ＜ 0.01 by Fisher’s exact test. 
¶p ＜ 0.05 by Student’s t-test. **p ＜ 0.01 by Student’s t-test. 
††p ＜ 0.001 by Student’s t-test. n.d.:
not done.
analysis (IFA) using the NDV antiserum or monoclonal 
antibodies specific to the NDV HN glycoprotein. Using 
IFA, the expressed glycoproteins were localized to the cell 
surface of the Sf21 cells infected with the recombinant 
baculovirus, rNDF(V), rNDF(L), rNDHN(V), and 
rNDHN(L) (data not shown).
    In Experiment 1, chickens inoculated with the crude 
extracts of Sf21 cells infected with the recombinant 
baculoviruses exhibited serological responses against 
NDV according to HI and ELISA (Table 2). The HI and 
ELISA titers of the first immunized groups were 
significantly higher than those of the non-immunized 
control except for the 10
4.0 dose of rNDHN(V) and 
rNDF(V) (Table 2). The HI titer of the 10
7.0 dose of 
rNDHN(L) was significantly lower than those of the 10
7.0 
(p ＜0.05), 10
6.0, and 10
5.0 doses (p ＜0.001) of rNDHN(V) 
after the first immunization. The 10
7.0 dose of rNDHN(V) 
induced a lower HI titer than those of the 10
6.0 and 10
5.0 
doses, but these differences were not statistically 
significant (p  ＞ 0.05). The HI titers after the second 
immunization were similar. However, the 10
7.0 dose of 
rNDHN(L) and the 10
4.0 dose of rNDHN(V) groups 
showed significantly higher titers than the first 
immunization (p ＜0.01). The ELISA titers of each group 
after the second immunization were significantly higher 
than the first immunization (Table 2), showing p ＜0.01 in 
groups given the 107.0 dose of rNDF(L) and the 10
6.0 and 
10
5.0 doses of rNDF(V), and p ＜0.05 in the group given the 
10
7.0 dose of rNDF(V). The protection efficacy of the 
recombinant glycoprotein was evaluated by a challenge 
after the second immunization (Table 2). Of the chickens 
immunized twice with each recombinant glycoprotein, 
80% (p ＜0.05) or 100% (p ＜ 0.01) survived the NDV 
challenge, whereas all unvaccinated birds died.
    In Experiment 2, further protective effects of each 
recombinant glycoprotein were examined (Tables 3 and 4). 
Although all the second immunized groups exhibited a 
similar protective effect as in Experiment 1, a 10
6.0 dose of 
the infected cells with the adjuvant was chosen to 
immunize the chickens based on the serological response 
and protective effect. The protective efficacy of a single 
dose of each of the four recombinant glycoproteins, a half 
dose of the two recombinant glycoproteins derived from 
vvNDV and the combined half dose of rNDF(V) and 
rNDHN(V)-infected cells were examined.
  Protective efficacy tests were performed after the first and 
second immunizations (Tables 3 and 4). The individual 
recombinant glycoproteins did not prevent clinical signs 
and mortality after the first immunization, except for the 
single dose of rNDHN(V), which had a protective effect 
against mortality (Table 3, p ＜0.01). The groups given the 
single dose of rNDHN(V) and half dose of rNDHN(V) 
showed a partial protective effect in terms of the clinical 
signs, but these were not statistically significant (p ＞ 
0.05). On the other hand, the group given the two 
glycoproteins, rNDF + HN(V), showed complete 
protection against the clinical signs and mortality (p ＜ 
0.001) following only the first immunization. The 
combined group did not show complete prevention from 
virus shedding from the oropharynx and cloaca, but the Protection of recombinant NDV subunit vaccine    305
Table 3. Protective effect in chickens after the 1st immunization with the recombinant baculovirus glycoproteins derived from the 
lentogenic and velogenic Newcastle disease viruses (Experiment 2)
Antigen 
immunized
Dose
(×10
6cells/bird)
Clinical signs
  Sick  MTO*
Mortality
Dead MDT
†
PI14
‡
Virus shedding
Oropharynx Cloaca
No. Titer
§ No. Titer
rND F (L) 1.0 7/7 4.4 4/7 5.0 1.57 7/7 10
4.0 6/7 10
3.0
rND F (V) 1.0 7/7 4.1 7/7 5.1 2.00 7/7 10
4.6 7/7 10
3.9
rND HN (L) 1.0 7/7 4.1 7/7 5.1 2.00 7/7 10
4.4 7/7 10
3.9
rND HN (V) 1.0 3/7 5.0 1/7
║ 7.0 0.57 7/7 10
3.4 7/7 10
2.3††
rND F (V) 0.5 7/7 4.0 7/7 5.0 2.00 7/7 10
4.6 7/7 10
4.0
rND HN (V) 0.5 3/7 4.3 3/7 5.3 0.86 7/7 10
3.7 6/7 10
2.3**
rND F+HN (V) 0.5+0.5 0/7
¶ -0 / 7
¶ -0 . 0 0 4 / 7 1 0
1.1†† 6/7 10
1.6††
Control - 7/7 4.0 7/7 5.0 2.00 7/7 10
4.7 7/7 10
4.1
*Mean time for the onset of clinical signs or death. 
†Mean death time. 
‡Pathogenicity index: the mean score per bird per observation
over a 14 day period when each day the birds were scored 0 if normal, 1 if sick, and 2 if dead. 
§Geometric mean titer (log10 TCID50/0.1
ml). 
∥p ＜0.01 by Fisher’s exact test. 
¶p ＜0.001 by Fisher’s exact test. **p ＜0.05 by Student’s t-test. 
††p ＜0.001 by Student’s t-test.
Table 4. Protective effect in chickens after the 2nd immunization with the recombinant baculovirus glycoproteins derived from the 
lentogenic and velogenic Newcastle disease viruses (Experiment 2)
Antigen 
immunized
Dose
(×10
6 cells/bird)
Clinical signs
  Sick  MTO*
Mortality
Dead MDT
†
PI14
‡
Virus shedding
Oropharynx Cloaca
No. Titer
§ No. Titer
rND F (L) 1.0 1/8** 7.0 1/8** 8.0 0.25 7/8 10
2.6†† 7/8 10
2.4
rND F (V) 1.0 0/7** -0 / 7 ** -0 . 0 0 7 / 7 1 0
2.4†† 5/7 10
1.6††
rND HN (L) 1.0 3/8
∥ 5.7 2/8
¶ 5.0 0.63 7/8 10
2.4†† 7/8 10
2.0††
rND HN (V) 1.0 0/8** -0 / 8 ** -0 . 0 0 7 / 8 1 0
2.9 6/8 10
1.5‡‡
rND F (V) 0.5 3/8
∥ 4.3 3/8
∥ 5.0 0.75 8/8 10
3.8 8/8 10
2.6
rND HN (V) 0.5 0/8** -0 / 8 ** -0 . 0 0 7 / 8 1 0
1.8‡‡ 7/8 10
1.3***
rND F+HN (V) 0.5+0.5 0/8** -0 / 8 ** -0 . 0 0 6 / 8 1 0
1.6*** 5/8 10
1.1‡‡
Control - 8/8 4.4 8/8 5.3 2.00 8/8 10
4.0 8/8 10
3.1
*Mean time for the onset of clinical signs or death. 
†Mean death time. 
‡Pathogenicity index: the mean score per bird per observation
over a 14 day period when each day the birds were scored 0 if normal, 1 if sick, and 2 if dead. 
§Geometric mean titer (log10 TCID50/0.1
ml). 
∥p ＜0.05 by Fisher’s exact test. 
¶p ＜ 0.01 by Fisher’s exact test. **p ＜ 0.001 by Fisher’s exact test. 
††p ＜ 0.05 by Student’s t-test.
‡‡p ＜ 0.01 by Student’s t-test. ***p ＜ 0.001 by Student’s t-test.
viral titers of this group were significantly lower (p ＜ 
0.001) than the non- immunized control group.
  Unlike the first immunization, the second immunization 
with the individual recombinant glycoprotein induced a 
protective effect against the clinical signs, mortality, and 
virus shedding with statistical significance (Table 4). The 
rNDF(L) and rNDHN(L) groups showed some clinical 
signs and mortality after the challenge, and the protective 
effects of these groups were significant compared with the 
control group (p ＜0.001, rNDF(L) group; p ＜0.05 and p 
＜0.01, rNDHN(L) group). The second immunization of 
the combined group, rNDF+HN(V), also induced a 
complete protective effect in terms of the clinical signs and 
mortality (p  ＜0.001) but the virus shedding still 
continued, albeit with the reduced titers, compared with the 
control group (p ＜0.001, oropharynx; p ＜0.01, cloaca).
Discussion
    The protective effect of individual F and HN 
glycoproteins of the virulent and avirulent strains of NDV 
and the synergistic effect of the combined F and HN 306    Youn-Jeong Lee et al.
glycoprotein were examined by inoculating recombinant 
baculovirus containing the glycoprotein genes intramuscularly 
into SPF chickens.
    Since 1984, genotype VII of NDV has become the 
dominant epizootic strain throughout Asia, Europe, and 
Africa. Recent epizootic strains of NDV in Korea also 
belong to genotype VII [11]. In this study, the F and HN 
glycoproteins of vvNDV were used to develop a more 
efficient subunit vaccine for preventing recent epizootic 
vvNDV infections.
  There are several conflicting reports regarding the effects 
of the individual NDV glycoproteins. According to 
Sakaguchi et al. [26], vaccination of chickens with the 
recombinant Marek’s disease virus serotype 1 (MDV1) 
expressing the F protein of lentogenic NDV D26 strain 
produced solid protection against a challenge. Mori et al. 
[19] reported that a recombinant baculovirus expressing 
the F protein of NDV D26 induced a protective effect. In 
contrast, Kamiya et al. [8] reported that the chickens 
immunized with rNDF or rNDHN proteins of the 
velogenic Miyadera strain (rMF or rMHN), the rNDHN 
protein of the D26 strain (rDHN), or a equal mixture of 
rMF and rMHN were completely protected from a 
subsequent challenge. However, chickens immunized with 
the rNDF protein of the lentogenic D26 strain (rDF) 
showed a lower protective efficacy.
  In this study, chickens immunized with each recombinant 
glycoprotein were protected (＞80%), after the second 
immunization, from a subsequent challenge with the lethal 
dose (10
5.5 EID50/bird) of the recent epizootic strain of 
vvNDV in Korea (Experiment 1). The chickens 
immunized with the recombinant fusion glycoprotein 
derived from the lentogenic La Sota strain, rNDF(L), and 
from vvNDV and rNDF(V), were also protected from a 
subsequent challenge. However, the ELISA titers of 
rNDF(L) were slightly lower than those of the rNDF(V) of 
the velogenic strain even though the difference was not 
statistically significant (p ＞ 0.05). The HI titers of the 
rNDHN protein of the lentogenic strain, rND HN(L), were 
significantly lower than those of rND HN(V) of the 
velogenic strain after the first immunization (p ＜0.05).
    The efficacy of the individual glycoprotein and the 
combined F and HN glycoproteins were investigated 
further (Experiment 2). The individual recombinant 
glycoproteins did not have a protective effect after the first 
immunization, even though the rNDHN(V)-immunized 
group appeared to be protected against mortality (p 
＜0.01). On the other hand, the combined inoculation of 
the two glycoproteins, rNDF+HN(V), produced complete 
protection against the clinical signs and mortality (p 
＜0.001) after only a single inoculation. Thus, the 
combined inoculation of the F and HN glycoproteins had a 
synergistic effect against a subsequent NDV challenge. 
Kamiya et al. [8] reported that chickens immunized with a 
mixture of rMF and rMHN developed a similar level of 
specific antibodies and protective efficacy compared with 
the chickens immunized with the individual glycoproteins. 
In this study, a synergistic effect of the combined 
inoculation of the F and HN glycoproteins was not detected 
after the second immunization, as reported by Kamiya et 
al. [8], even though it could be recognized after the first 
inoculation, in which the individual glycoproteins rarely 
induced a protective effect. Also, a single inoculation of 
the combined recombinant glycoprotein was sufficient to 
induce a protective effect, whereas the individual rND 
protein needed a booster immunization to induce 
protection.
    Booster immunization of the individual recombinant 
glycoproteins of vvNDV greatly increased their protective 
efficacy. However, the rNDF and rNDHN proteins of the 
lentogenic strain had a slightly lower protective efficacy in 
the clinical signs and mortality even after the booster 
immunization, although this difference was not 
statistically significant (Experiments 1 and 2).
  Newcastle disease vaccinations generally protect birds 
from the more serious consequences of the disease but 
virus replication and shedding still occur in the infected 
birds after vaccination, albeit at reduced levels [2]. In this 
study, chickens immunized with the recombinant 
glycoprotein were protected against the clinical signs and 
mortality but virus shedding still occurred, as described in 
previous studies using live and inactivated vaccines 
[1,5,25,29,31,32]. Vaccination with the recombinant 
glycoprotein did not completely inhibit virus shedding 
from the oropharynx and cloaca but the viral titer was 
significantly lower than in the non-immunized control 
group.
  This study evaluated the protective effect of individual 
recombinant glycoproteins derived from velogenic and 
lentogenic NDV strains. The recombinant glycoproteins 
from the virulent strain produced complete protection after 
the second immunization, whereas those from the 
lentogenic strain had a slightly lower protective effect. 
Thus, there is a synergistic effect of the combined F and 
HN glycoprotein, and the use of a subunit vaccine 
composed of the two glycoproteins can offer good 
protection against NDV. Although virus shedding still 
occurred after immunization with NDV glycoproteins, the 
reduced viral titer would be meaningful in the control of 
vvND outbreaks. A recombinant subunit marker vaccine 
should be further examined to establish future control and 
eradication strategies for ND.
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